This difference was not statistically significant.[90][Level of evidence B1]Because of adverse events, abemaciclib dose adjustments occurred in 1,901 patients (68.1%); 56.9% of these patients had dose omissions and 41.2% had dose reductions.
In the abemaciclib arm, 463 patients (16.6%) discontinued abemaciclib because of adverse events, 306 of whom remained on endocrine therapy.[89]Similar results were found in a prespecified subgroup analysis of patients who had received neoadjuvant chemotherapy and had residual disease after surgery.[91] At a median follow-up of 54 months, an analysis showed that adding abemaciclib resulted in a substantial improvement in IDFS (5-year IDFS: 76% vs.